great news, thanks for clarification there nuts
avastin only seems to be specific to those who are platinum-resistant (platinum being a main constituent of common chemo), so not marketed for all OC sufferers
the fact that it only showed a PFS of 3.3 months greater than SoC is encouraging, especially given the relative lack of side effects that Cvac has
we really need final phaseIIb data to come in, and be positive.
time to commercialisation might be a way off, but if the phaseIIb data suggests that phase III will be significant, then you should expect a positive re-rating of the stock. but that is IF it is positive.....
success for avastin in europe, page-9
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |